Journal
ONCOIMMUNOLOGY
Volume 1, Issue 3, Pages 326-333Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/onci.18852
Keywords
regulatory T cell; antiangiogenic molecule; CCR4; chemokine
Categories
Funding
- Canceropole Ile de France
- ANR (Agence Nationale de la Recherche)
- Ligue contre le Cancer
- Association pour la Recherche sur le Cancer
- Institut National du Cancer
- Centre d'investigation Clinique en Biotherapie [CIC-BT505]
- Labex Immuno-Oncology
Ask authors/readers for more resources
CD4(+)CD25(+)Foxp3(+) regulatory T cells (Treg) have emerged as a dominant T cell population inhibiting anti-tumor effector T cells. Initial strategies used for Treg-depletion (cyclophosphamide, anti-CD25 mAb ...) also targeted activated T cells, as they share many phenotypic markers. Current, ameliorated approaches to inhibit Treg aim to either block their function or their migration to lymph nodes and the tumor microenvironment. Various drugs originally developed for other therapeutic indications (anti-angiogenic molecules, tyrosine kinase inhibitors, etc) have recently been discovered to inhibit Treg. These approaches are expected to be rapidly translated to clinical applications for therapeutic use in combination with immunomodulators.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available